Cushing Syndrome

Latest News

Levoketoconazole Effectively Treats Endogenous Cushing Syndrome in Phase 3 Trial

By

Amit Akirov, MD

According to results of the phase 3 SONICS trial, levoketoconazole is a safe and effective treatment option for patients with Cushing syndrome.

Sex Affects Clinical Presentation of ACTH-Dependent Cushing Syndrome

By

Morgan E. Meissner

Researchers examined sex differences in clinical presentation and patient outcomes in ACTH-dependent Cushing syndrome.

Signs and Symptoms of Adrenal Medullary Hyperplasia vs Pheochromocytoma

By

Hannah Dellabella

Patients with AMH without pheochromocytoma had milder symptoms compared with patients with pheochromocytoma only.

Mifepristone an Effective Alternative to Surgery for Patients With Bilateral Macronodular Adrenal Hyperplasia

By

Tyler Rice

Mifepristone may be an effective alternative to adrenalectomy in patients with hypercortisolism caused by primary bilateral macronodular adrenal hyperplasia.

Transsphenoidal Surgery Recommended for Cushing Disease With Inconclusive or Normal MRI

By

Amit Akirov, MD

In the absence of clear evidence of a pituitary adenoma on imaging, there is some controversy regarding the best treatment for Cushing disease.

High Prevalence of Diabetes in Patients With Primary Aldosteronism

By

Endocrinology Advisor Contributing Writer

Prevalence of diabetes is higher in patients with primary aldosteronism and was found to be related to suspected subclinical hypercortisolism.

New Data for Potential Cushing Syndrome Treatment Levoketoconazole Announced

By

Da Hee Han, PharmD

Researchers reported that mean urinary-free cortisol (mUFC) normalization with Recorlev was similar in patients with and without diabetes.

Elevated Plasma Agouti-Related Protein May Be a Marker for Cushing Disease

By

Roxanne Nelson, BSN, RN

Plasma levels of the orexigenic neuropeptide agouti-related protein (AgRP) are elevated in Cushing disease, and it may be a marker of hypothalamic AgRP.

Positive Results for Recorlev in Phase 3 Cushing Syndrome Trial

Results from this single-arm, open-label study found that 30% of patients achieved normalization of mean urinary free cortisol (UFC) after 6 months of maintenance treatment with levoketoconazole, without a dose increase (P<.25).

Cardiovascular Function May Improve After Cure of Cushing Syndrome

By

Virginia Schad, PharmD

Study assessed cardiovascular function, quality of life, and mental/physical health in overt and cured Cushing syndrome.

New Research Highlights Possible Genetic Cause of Cushing’s Disease

By

Brian Ellis

The analysis led to the identification of 4 potentially pathogenic missense variants in CABLES1.